A Study to Assess the Effect of the Natural Orange Extract in Individuals With Gastrointestinal Discomfort
NCT ID: NCT06658717
Last Updated: 2024-10-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
64 participants
INTERVENTIONAL
2024-10-15
2025-01-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Citrus Extract on Oxidative Stress
NCT03580447
Assessment of Bioavailability of Phenolics From an Orange Peel Extract
NCT02033330
Effects of Pomegranate Extract on Intestinal Flora
NCT02370641
Citrus Beverages and Gastrointestinal Function
NCT02979496
Impacts of a Combined Berry Extract Supplement on Vascular Function and Oxygen Utility Capacity in Young Adults
NCT04312022
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I: Investigational product (IP)
One capsule to be taken with breakfast orally once a day
Investigational product (IP): Natural orange extract
Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
Placebo: Microcrystalline cellulose (MCC)
One capsule to be taken with breakfast orally once a day
Group II: Placebo: Microcrystalline cellulose (MCC)
Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Investigational product (IP): Natural orange extract
Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
Group II: Placebo: Microcrystalline cellulose (MCC)
Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Healthy males and females of age between 18-65 years.
3. Individuals with a Body Mass Index (BMI) between 18.5-29.9 kg/m2 (both values included).
4. Individuals with a history of GI discomfort, associated with changes in the frequency and form of stools for the last 3 months, with symptom onset at least 6 months.
5. Individuals with complaints of loose or watery stools, occurring in more than 25% of stools for the last 3 months.
6. Individuals with consistent and stable body weight in the last 3 months prior to screening (less than 5% self-reported change).
7. Individuals with a baseline score of less than or equal to 55 for the digestive domain score of the Gastrointestinal Quality of Life Index (GIQLI).
8. Individuals with Fasting Blood Glucose (FBG) less than equal to 125 mg/dl.
9. Individuals with systolic blood pressure (SBP) less than 140 and/or diastolic blood pressure (DBP) less than 90 mm Hg.
10. Individuals willing to avoid consumption of citrus-based products during the entire study duration.
11. Individuals willing to follow all the study procedures and follow-up visits as per protocol.
Exclusion Criteria
2. Individuals diagnosed with hypertension and are on active medication.
3. Individuals with thyroid dysfunction as assessed by Thyroid Stimulating Hormone (TSH) less than or equal to 0.4 or more than or equal to 5.0 mIU/L will be excluded.
4. Individuals with a history and/or presence of acute or chronic significant GI disease or digestion/absorption disorders (e.g., Irritable bowel syndrome, inflammatory bowel disease, infectious diarrhea, coeliac disease, Clostridium difficile colitis, malabsorption, pancreatitis, disorders in digestive tract motility, gluten enteropathy, etc).
5. Individuals with a history of autoimmune disorders.
6. Individuals with major gastric, hepatic, biliary, pancreatic, or intestinal surgery within the last 6 months prior to screening or planned during the study (appendectomy, haemorrhoidectomy, or polypectomy allowed as long as occurred more than 3 months prior to screening; uncomplicated laparoscopic or open cholecystectomy is allowed if no history of post-operative biliary tract pain and surgery occurred more than 3 months prior to screening).
7. Any other relevant serious organ or systemic diseases (e.g., cardiovascular, respiratory, liver, renal, neurological disease, etc).
8. Individuals with a history of malignancy within last five years.
9. Use of immunosuppressive drugs within 3 months prior to the screening.
10. Use of oral corticosteroids within 1 month prior to the screening.
11. Excessive alcohol drinking (For men, consuming five or more drinks on any day or 15 or more per week; for women, consuming four or more on any day or 8 or more drinks per week). One unit of alcohol is equal to 45 ml of hard liquor, 150 ml of wine or a pint of beer.
12. Individuals with a history of/known allergies to citrus fruits or citrus-based products.
13. Individuals taking any antibiotics in the past 4 weeks and during the study.
14. Individuals who are on regular intake of laxatives in the past 1 month prior to the screening.
15. Individuals taking any dietary supplements, and medication for any gastrointestinal or metabolic disease (peptic ulcer, IBS, type-II diabetes, atherosclerosis, etc.)
16. Individuals taking any hormones for any gastrointestinal or metabolic disease within 3 months prior to screening.
17. Individuals taking any probiotics, prebiotics, post-biotics or synbiotics within 3 months prior to the screening.
18. History of smoking or currently smoking.
19. Individuals with gluten and/or lactose intolerance.
20. Females who are pregnant/lactating or planning to be pregnant.
21. Individuals who have participated in another clinical study(ies) with an IP within 90 days before screening, or who plan to participate in another study during the study period.
22. Any other conditions, which in the opinion of the investigator may jeopardize the study.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vedic Lifesciences Pvt. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pawna Hospital
Pune, Maharashtra, India
Shree Samarth Hospital
Pune, Maharashtra, India
Shivam Hospital
Thāne, Maharashtra, India
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HT/240501/CARD/GID
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.